West German Cancer Center, Department of Gynecology and Obstetrics, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany.
West German Cancer Center, Department of Gynecology and Obstetrics, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany -
Minerva Ginecol. 2020 Dec;72(6):399-403. doi: 10.23736/S0026-4784.20.04691-2. Epub 2020 Nov 3.
Lymph node involvement is an important prognostic factor in early and advanced epithelial ovarian cancer (EOC). However, to date there is no reliable method of detecting lymph node involvement, apart from surgical staging. Thus, pelvic and paraaortic lymphadenectomy (LNE) are still part of standard surgery of early ovarian cancer. There is conflicting evidence about the therapeutic value of systematic LNE in early EOC. Thus, the developmemt of a method to predict nodal status accurately, without extensive LNE, is the subject of ongoing research. Sentinel lymphadenectomy (SLN) has become a standard procedure in oncological surgery. However, SLN is not yet an established and widely accepted procedure for EOC. This review aimed at summarizing available evidence on its feasibility and reliability in EOC. Overall, evidence of SLN in early EOC is still scarce. So far, only small series of patients with a variety of tracers and injection sites were published. From the available literature, the most promising technique seems to be injection into the infundibulopelvic, as well as the proper ovarian ligament. Indocyanine green seems to be an excellent tracer for successful SLN of ovarian tumors, which can be used during laparoscopic or robotic surgery. The detection rates and true positive rates of studies support further investigation of the technique. Results from prospective studies, e.g. the ongoing SELLY trial, are necesssary to implement SLN into the standard treatment of early EOC.
淋巴结受累是早期和晚期上皮性卵巢癌 (EOC) 的重要预后因素。然而,迄今为止,除了手术分期外,尚无可靠的方法来检测淋巴结受累。因此,盆腔和腹主动脉旁淋巴结切除术 (LNE) 仍然是早期卵巢癌标准手术的一部分。系统 LNE 在早期 EOC 中的治疗价值存在争议。因此,开发一种无需广泛 LNE 即可准确预测淋巴结状态的方法是正在进行的研究课题。前哨淋巴结切除术 (SLN) 已成为肿瘤外科的标准程序。然而,SLN 尚未成为 EOC 的既定且广泛接受的程序。这篇综述旨在总结其在 EOC 中可行性和可靠性的现有证据。总体而言,早期 EOC 中 SLN 的证据仍然很少。迄今为止,仅发表了各种示踪剂和注射部位的小系列患者。从现有文献来看,最有前途的技术似乎是向漏斗骨盆和卵巢固有韧带注射。吲哚菁绿似乎是成功进行卵巢肿瘤 SLN 的理想示踪剂,可用于腹腔镜或机器人手术。研究的检出率和真阳性率支持对该技术进行进一步研究。前瞻性研究(例如正在进行的 SELLY 试验)的结果对于将 SLN 纳入早期 EOC 的标准治疗中是必要的。